As the COVID-19 Pandemic Continues, Fewer Patient-Physician Encounters Suggest Later-Stage Disease at PresentationOctober 31st 2020
A report demonstrated the potential impact of COVID-19 on cancer-related patient encounters, which may result in an increase in the presentation of later-stage disease for newly diagnosed patients in future months.
Targeting HRAS Mutations With Investigational Tipifarnib May Hold Promise in Some Tumor TypesOctober 30th 2020
The high variability in responses among different types of HRAS-altered cancers highlights the need to identify rational therapeutic combinations that enhance response to HRAS-directed therapies.
Across Cancer Settings, ICIs Continue to Make Deep InroadsOctober 27th 2020
With immune checkpoint inhibitors gaining widespread adoption, their optimal use hinges on a greater understanding of biomarkers, practical applications, and their potential in combination with cellular therapies.
How to Leverage Real-World Data as COVID-19 Transforms Clinical TrialsOctober 27th 2020
Due to efforts to reduce exposure to the coronavirus, oncology patient volumes initially decreased, treatment regimens were disrupted or altered, and new cancer diagnoses also slowed. This affected not only patient care, but also clinical trials.
CLL Treatment Further Refined With Venetoclax Data UpdatesOctober 27th 2020
The introduction of venetoclax into the treatment paradigm of chronic lymphocytic leukemia has led to options for time-limited therapy in a space that has been dominated by continuous therapeutic agents.
TNBC Heterogeneity Opens Door for Emerging Targeted TherapiesOctober 26th 2020
As a greater understanding of triple-negative breast cancer heterogeneity develops over time, combinations of PD-1/PD-L1 plus PARP inhibitors, androgen receptor targeted agents, and PI3K/AKT/mTOR pathway inhibitors are undergoing evaluation by investigators in the field.
Optimizing Benefit in Targeted Therapies Requires Multipronged Educational ApproachOctober 25th 2020
Much is still unknown about the cancer process and how targeted therapies work on specific tumor vulnerabilities. Providers must closely follow evolving information, especially regarding adverse events.
Expert Reviews Novel Strategies in the Pipeline for the Treatment of ER-Positive Breast CancerOctober 22nd 2020
Recent acceleration in the introduction of new regimens for the treatment of estrogen receptor–positive breast cancer has led to significant survival enhancement, but questions remain regarding how patients should be stratified following disease progression with these therapies.
Investigators Tailor TNBC Therapy Using Genomic AlterationsOctober 21st 2020
In a presentation at the 2020 Lynn Sage Breast Cancer Symposium, Virginia G. Kaklamani, MD, DSc, reviewed the current genomic tools in the triple negative breast cancer landscape that predict response to targeted treatments.
New ASH Guidelines Highlight a Call to Action for Treatment of Older AML PatientsOctober 20th 2020
New guidelines from he American Society of Hematology for treating newly diagnosed acute myeloid leukemia in older patients recommend intensive antileukemic therapies over more conservative approaches.
Treatment Options for HER2+ Breast Cancer Open to Multiple Lines of Therapy and SubgroupsOctober 20th 2020
Until recently, few options existed for patients with HER2-positive breast cancer who progressed on earlier lines of therapy. Recent approvals of 3 drug combinations offer new tools that may prolong life and control brain metastases across lines of therapy.